Tarsus Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation

Tarsus Pharmaceuticals released its Q4 2025 earnings presentation, detailing financial performance and operational updates during its quarterly investor call in February 2026. The slide deck, published alongside the earnings call, provided key metrics, including revenue growth, R&D investments, and pipeline progress for its ophthalmic and dermatologic therapies. No specific financial figures were disclosed in the transcript summary, but the presentation likely addressed commercialization strategies for its lead drug, TP-03, targeting Demodex blepharitis. The company emphasized expansion plans, including potential regulatory milestones and market penetration efforts in the U.S. and internationally. Seeking Alpha’s transcripts team compiled the materials as part of its ongoing coverage of public company earnings, offering investors direct access to executive commentary.